BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
| Revenue (Most Recent Fiscal Year) | $221.90M |
| Net Income (Most Recent Fiscal Year) | $-535.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 42.62 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | -- |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -331.52% |
| Net Margin (Trailing 12 Months) | -329.25% |
| Return on Equity (Trailing 12 Months) | -- |
| Return on Assets (Trailing 12 Months) | -85.69% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.19 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.08 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | -- |
| Inventory Turnover (Trailing 12 Months) | 1.61 |
| Book Value per Share (Most Recent Fiscal Quarter) | $-9.30 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.95 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.27 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.09 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 191.17M |
| Free Float | 156.38M |
| Market Capitalization | $10.05B |
| Average Volume (Last 20 Days) | 3.00M |
| Beta (Past 60 Months) | 1.23 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 18.20% |
| Percentage Held By Institutions (Latest 13F Reports) | 99.85% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |